J. THORNTON to Humans
This is a "connection" page, showing publications J. THORNTON has written about Humans.
Connection Strength
0.499
-
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.
Score: 0.026
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
Score: 0.026
-
Characterising incident opioid use among incident users of prescription sedative hypnotics: A national cohort study. BMJ Open. 2024 05 30; 14(5):e082339.
Score: 0.025
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
Score: 0.024
-
Productivity Loss Among Opioid and Benzodiazepine Users in the United States: A Medical Expenditure Panel Survey From 2010 to 2019. J Occup Environ Med. 2024 03 01; 66(3):226-233.
Score: 0.024
-
Physician perspective on the implementation of risk mitigation strategies when prescribing opioid medications: a qualitative analysis. BMC Health Serv Res. 2023 Oct 31; 23(1):1185.
Score: 0.024
-
Differences in Perceived Threat and Efficacy in Managing Opioid Use Disorder versus Alcohol Use Disorder. Subst Use Misuse. 2023; 58(10):1187-1195.
Score: 0.023
-
Parents' intention to have their child vaccinated at a community pharmacy: A national cross-sectional survey. J Am Pharm Assoc (2003). 2023 Mar-Apr; 63(2):511-517.e8.
Score: 0.022
-
Intention to get naloxone among?patients prescribed opioids for chronic pain. Harm Reduct J. 2022 Sep 22; 19(1):104.
Score: 0.022
-
Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder. J Pain Palliat Care Pharmacother. 2022 Jun; 36(2):103-111.
Score: 0.022
-
Association of cash payment with intensity of opioid prescriptions. J Am Pharm Assoc (2003). 2022 Jul-Aug; 62(4):1224-1231.e5.
Score: 0.021
-
Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas. Pharmacoepidemiol Drug Saf. 2021 04; 30(4):492-503.
Score: 0.020
-
Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020 12; 14(6):e372-e374.
Score: 0.020
-
Does Social Desirability Influence Preceptors' Completion of Student Experiential Evaluations? Am J Pharm Educ. 2020 09; 84(9):ajpe7949.
Score: 0.019
-
Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach. Int J Drug Policy. 2020 09; 83:102827.
Score: 0.019
-
Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications. Res Social Adm Pharm. 2021 01; 17(1):2005-2008.
Score: 0.019
-
Prescription drug disposal: Products available for home use. J Am Pharm Assoc (2003). 2020 Jul - Aug; 60(4):e7-e13.
Score: 0.018
-
Health-related quality of life in patients receiving long-term opioid therapy: a systematic review with meta-analysis. Qual Life Res. 2017 08; 26(8):1955-1967.
Score: 0.015
-
Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc (2003). 2017 Mar - Apr; 57(2S):S12-S18.e4.
Score: 0.015
-
Car Seat Safety: Typologies of Protective Health and Safety Behaviors for Mothers in West Virginia. Matern Child Health J. 2017 02; 21(2):326-334.
Score: 0.015
-
Re: Saunders R, Lian J, Karolicki B, Valentine W. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. J Med Econ 2014;17(12):827-36. J Med Econ. 2015 Jun; 18(6):433-4.
Score: 0.013
-
Impact of automated alerts on discharge opioid overprescribing after general surgery. Am J Health Syst Pharm. 2024 Dec 05; 81(24):1288-1296.
Score: 0.006
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.006
-
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors. Am J Clin Oncol. 2024 Nov 01; 47(11):517-525.
Score: 0.006
-
Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States. Oncologist. 2024 Feb 02; 29(2):176-184.
Score: 0.006
-
Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors. BMC Cancer. 2023 Jul 13; 23(1):655.
Score: 0.006
-
Identifying predictors of generalized anxiety among student pharmacists in response to the COVID-19 pandemic. Curr Pharm Teach Learn. 2023 01; 15(1):34-42.
Score: 0.006
-
Optimization of Opioid Discharge Prescriptions Following Thyroid and Parathyroid Surgery. Otolaryngol Head Neck Surg. 2023 Jul; 169(1):176-184.
Score: 0.006
-
Trends and patterns in the use of opioids among metastatic breast cancer patients. Sci Rep. 2020 12 10; 10(1):21698.
Score: 0.005
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.005
-
Prolonged Opioid Use After Surgery for Early-Stage Breast Cancer. Oncologist. 2020 10; 25(10):e1574-e1582.
Score: 0.005
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.005
-
Prescribers' perceptions on the impact of hydrocodone rescheduling on geriatric pain management: A qualitative study. J Opioid Manag. 2018 Sep/Oct; 14(5):317-326.
Score: 0.004